Item Type | Name |
Concept
|
Multiple Sclerosis
|
Concept
|
Multiple Sclerosis, Chronic Progressive
|
Concept
|
Multiple Sclerosis, Relapsing-Remitting
|
Academic Article
|
Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.
|
Academic Article
|
Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b.
|
Academic Article
|
Activated IL-1RI Signaling Pathway Induces Th17 Cell Differentiation via Interferon Regulatory Factor 4 Signaling in Patients with Relapsing-Remitting Multiple Sclerosis.
|
Academic Article
|
Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: implications for the initiation of the autoimmune response in multiple sclerosis.
|
Academic Article
|
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
|
Academic Article
|
IL-11 in multiple sclerosis.
|
Academic Article
|
Degenerate T-cell receptor recognition, autoreactive cells, and the autoimmune response in multiple sclerosis.
|
Academic Article
|
IL-11 Induces Th17 Cell Responses in Patients with Early Relapsing-Remitting Multiple Sclerosis.
|
Academic Article
|
B cells as a therapeutic target for IFN-ß in relapsing-remitting multiple sclerosis.
|
Academic Article
|
IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation.
|
Academic Article
|
Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis.
|
Academic Article
|
T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans.
|
Academic Article
|
High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis.
|
Academic Article
|
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
|
Academic Article
|
Diffusion tensor imaging based network analysis detects alterations of neuroconnectivity in patients with clinically early relapsing-remitting multiple sclerosis.
|
Academic Article
|
A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis.
|
Academic Article
|
CD4+CD28- costimulation-independent T cells in multiple sclerosis.
|
Academic Article
|
Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis.
|
Academic Article
|
CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients.
|
Academic Article
|
The initiation of the autoimmune response in multiple sclerosis.
|
Academic Article
|
Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis.
|
Academic Article
|
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
|
Academic Article
|
IFN-beta inhibits human Th17 cell differentiation.
|
Academic Article
|
Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response.
|
Academic Article
|
Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells.
|
Academic Article
|
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly.
|
Academic Article
|
Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate.
|
Academic Article
|
Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.
|
Academic Article
|
Molecular mimicry and antigen-specific T cell responses in multiple sclerosis and chronic CNS Lyme disease.
|
Academic Article
|
The role of endogenous IFN-ß in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis.
|
Academic Article
|
Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
|
Academic Article
|
Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes.
|
Academic Article
|
Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair.
|
Academic Article
|
Oral simvastatin treatment in relapsing-remitting multiple sclerosis.
|
Academic Article
|
Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis.
|
Academic Article
|
Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis.
|
Academic Article
|
Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
|
Academic Article
|
The role of fractalkine (CX3CL1) in regulation of CD4(+) cell migration to the central nervous system in patients with relapsing-remitting multiple sclerosis.
|
Academic Article
|
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
|
Academic Article
|
Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis.
|
Academic Article
|
Immunopathogenesis of the multiple sclerosis lesion.
|
Academic Article
|
Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis.
|
Academic Article
|
IL-11 antagonist suppresses Th17 cell-mediated neuroinflammation and demyelination in a mouse model of relapsing-remitting multiple sclerosis.
|
Academic Article
|
Case Report: Combining Dalfampridine with Multicomponent Exercise and Gait Training in a Person with Multiple Sclerosis.
|
Academic Article
|
IL-11 Induces Encephalitogenic Th17 Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.
|
Academic Article
|
Therapeutic Effect of Anti-CD52 Monoclonal Antibody in Multiple Sclerosis and Its Animal Models Is Mediated via T Regulatory Cells.
|
Academic Article
|
Dalfampridine for Mobility Limitations in People With Multiple Sclerosis May Be Augmented by Physical Therapy: A Non-randomized Two-Group Proof-of-Concept Pilot Study.
|